Search results
Results from the WOW.Com Content Network
Although anxiety can temporarily increase as a withdrawal symptom, there is evidence that a reduction or withdrawal from benzodiazepines can lead to a reduction of anxiety symptoms in the long run. [4] [5] Due to these increasing physical and mental symptoms from long-term use of benzodiazepines, slow withdrawal is recommended for long-term users.
The committee found that the regular use of benzodiazepines causes the development of dependence characterized by tolerance to the therapeutic effects of benzodiazepines and the development of the benzodiazepine withdrawal syndrome including symptoms such as anxiety, apprehension, tremors, insomnia, nausea, and vomiting upon cessation of ...
Treatment for withdrawal usually involves weaning over a 3- to 21-day period if the infusion lasted for more than a week. [134] Symptoms include tremors, agitation, sleeplessness, inconsolable crying, diarrhea and sweating. In total, over fifty withdrawal symptoms are listed in this review article.
Anxiety medications. Anxiety medications called benzodiazepines like alprazolam (Xanax®) , diazepam (Valium®), and clonazepam (Klonopin®) can be used to quickly reduce anxiety attack symptoms.
In addition to treating anxiety and seizures, clonazepam also has off-label uses for restless leg syndrome, acute mania, insomnia and the neurological condition tardive dyskinesia, which causes ...
Clonazepam, sold under the brand name Klonopin among others, is a benzodiazepine medication used to prevent and treat anxiety disorders, seizures, bipolar mania, agitation associated with psychosis, obsessive–compulsive disorder (OCD), and akathisia. [11]
Clonazepam, an anxiety drug, is being voluntarily recalled for the potential to cause a “life-threatening” event. ... The oral medication is commonly used to provide “a calming effect on the ...
There is some evidence that a prior history of CNS depressant dependence (e.g. alcohol) increases the risk of dependence on benzodiazepines. Tolerance to drugs is commonly believed to be due to receptor down-regulation; however, there is very limited evidence to support this, and this hypothesis comes from animal studies using very high doses.